iSpecimen Inc. today announced it has been selected to support new research related to COVID-19. This project aims to identify the transmissibility, variants, and testing validity of COVID-19 in various populations. ISPC stock soars 81% today, jumping to the price of $18.52. iSpecimen is pleased to support new research on COVID-19, which is seeking to improve the diagnostic accuracy and utility of the drug. Through its extensive experience in the biospecimen industry, iSpecimen is well-suited to support these types of projects. The Company’s work with COVID-19 started right after the rash. It provided the CDC with 600 serum samples and 100 negative samples, mostly remnants of lab tests.
Custom COVID-19 collections are also available from various federal offices and private organizations. A project carried out by iSpecimen involves enlisting the help of household members and other individuals who may be affected by COVID-19 testing. These individuals can then schedule a follow-up test if they develop COVID-19 symptoms after being subjected to the test. The patients with positive COVID-19 give their blood samples to the company. Each sample type is collected across a variety of geographic regions and ethnicities. In some cases, variants are identified by carefully sequencing the samples to identify potential variants.